Print

Purpose

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

Condition

Eligibility

Eligible Ages
Between 18 Years and 99 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of pancreatic ductal adenocarcinoma - Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies - Patients must have adequate organ function

Exclusion Criteria

  • Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation - Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention - Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation - Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy - Clinically significant cardiovascular disease - Uncontrolled hypertension - Inability to swallow tablets

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cabozantinib and pembrolizumab
  • Drug: Cabozantinib
    Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
  • Drug: Pembrolizumab
    Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).

Recruiting Locations

UK Center for Clinical and Translational Science and nearby locations

University of Kentucky Markey Cancer Center
Lexington, Kentucky 40536
Contact:
Joseph Kim, MD
859-257-4490
joseph.kim@uky.edu

More Details

NCT ID
NCT05052723
Status
Recruiting
Sponsor
Joseph Kim

Study Contact

Joseph Kim, MD
859-257-4490
joseph.kim@uky.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.